Next Leg Getting Ready to Jump!
We're Talking a Massive Short Squeeze with Good News! 16 plus Days to Cover!
Plus Tutes Holdings Grew!
Float in TROV is Tiny!
Back Fill and Move Forward! I Think Pepsi!
More Shorts are Covering! Count has Dropped again!
I think the Tide has Finally Changed in TROV!
Lets see what the Outcome could Be?
Have a Great Trading Day!
8:32 am TrovaGene enters into a broad collaboration agreement with USC Norris Comprehensive Cancer Center to establish a standardized framework for Trovera urine liquid biopsy testing (TROV) :
Trovera urine and blood-based EGFR, KRAS and BRAF CLIA and CAP-accredited tests are available for the detection and/or monitoring of tumor dynamics before, during, and after treatment.
This collaboration will seek to establish a standardized framework for the use of Trovera urine liquid biopsy testing at USC as well as to define practical considerations and best practices for liquid biopsy testing from urine, according to the co.
The collaboration will also explore the development of clinical treatment algorithms through investigational studies to solidify how and when liquid biopsy testing can be employed, according to the co.
Trovagene and USC Norris Comprehensive Cancer Center Collaborate to Standardize the Use of Trovera™ ctDNA Liquid Biopsy Tests in Patient Care!
This will be a Multi Billion $ Company!
Although surgery is the only therapeutic means of cure, less than 20% are found fit to undergo resection, primarily due to late diagnosis of the disease. This is where Trovera – built upon TrovaGene’s Precision Cancer Monitoring (PCM) platform – has significant utility as it can rapidly detect KRAS gene mutation, which occurs in almost 90% of pancreatic carcinomas.
Moreover, according to Diane Simeone, M.D., director of the Pancreatic Cancer Center at the University of Michigan Comprehensive Cancer Center, “The Trovagene assay will allow us to quickly test multiple therapies to determine which one will be most effective in treating an individual patient's tumor."
The latest collaboration reflects TrovaGene’s focus on expanding the market opportunity for Trovera. The University of Michigan Cancer Center is one of only 45 centers in the U.S. to earn the National Cancer Institute's most coveted "comprehensive" designation. The University of Michigan is also one of the best hospitals in the U.S. for cancer treatment.
Bids are Coming in!
Shorts have 12 Days to Cover and I Feel they're Under Estimating the Potential of TROV!
Once this Gets Lit this will Run Hard!
This MU Partnership is such a Big Deal!
The Street will come Around Soon!
Can't be Ignored!